What I found interesting in the PR... is this: " Kevetrin has reached its initial clinical stage goal of Phase 1 human trials for solid tumors and the protocol is now being written for clinical trials in blood cancers at university-sponsored studies in Europe." and MORE importantly it was followed by: “These advancements for a small biotech company could not have been possible without the dedication and passion our whole team demonstrated working on Kevetrin,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Kevetrin has shown in laboratory studies to activate p53, ‘the Guardian Angel Gene,’ to reduce tumor volume and slow tumor progression in cancers which other drugs were ineffective in doing so. A completely new class in chemistry, we believe that our novel drug is something that the cancer industry has been in search of for decades. We have extremely high expectations for Kevetrin.”
If they are looking at the dosing data and there was NO sign of P53 activation there is no way they put that paragraph in the PR (eventhough that paragraph has been used in other PRs). IMO, they have proof of P53 activation but are being incredibly cautious (as they should be).
I've always been a bit skeptical of sure thing stocks, but I'm quickly becoming a true believer.
